As the sponsor of clinical studies with the investigational medicinal product (IMP) specified above, Bristol-Myers Squibb Research & Development is issuing this safety report. The details of this adverse event/safety issue are being reported to you in compliance with regulations.
For Suspected Unexpected Serious Adverse Reactions (SUSARs) occurring in blinded clinical trials, study treatments will remain blinded in reports sent to investigators.
The attached report does not reflect a conclusion or constitute an admission by the sponsor that the IMP caused or contributed to this adverse event/safety issue.
Your Institutional Review Board (IRB)/Ethics Committee (EC) must receive a copy of this SUSAR as per applicable regulation and local IRB/EC policy. Please consult the clinical trial personnel or documents/manuals regarding your responsibility for submitting SUSARs to your IRB/EC. Please also review your IRB/EC procedures relating to adverse events/safety issues that may necessitate changes to the Informed Consent Form.
Please include this SUSAR with all copies of the Reference Document.
We thank you in advance for your prompt attention to this information.